🔍

FORTIS - Fortis Health.

📊 NSE: FORTIS 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:09

📢 Recent Corporate Announcements

Fortis Promoter NTK's Case Against Daiichi: Tokyo Court Judgment Set for Sept 10, 2026

🔵 WATCH ⭐ 8/10

LEGAL 📅 29 Apr 2026, 01:48 PM

Northern TK Venture Pte Ltd (NTK), the promoter shareholder of Fortis Healthcare and a subsidiary of IHH Healthcare, is engaged in material litigation against Daiichi Sankyo in the Tokyo District Court. The court has concluded preparatory and oral proceedings regarding NTK's claim. A final judgment is now scheduled to be delivered on September 10, 2026. This legal battle is a critical component of the long-standing issues surrounding IHH's acquisition of Fortis and the pending mandatory open offer.

Tokyo District Court has concluded oral proceedings in the litigation filed by NTK against Daiichi Sankyo.
The court is scheduled to announce its judgment on September 10, 2026.
The litigation is linked to the mandatory open offer for an additional 26.10% stake in Fortis Healthcare.
NTK is an indirect wholly-owned subsidiary of IHH Healthcare Berhad, the promoter of Fortis.

💡 Investors should monitor the legal developments as the judgment in September 2026 will be a significant milestone for the completion of the pending open offer. The stock remains sensitive to these legal proceedings which impact the finality of the IHH-Fortis transaction.

Fortis Healthcare Grants 1.32 Crore ESOPs at Exercise Price of Rs 923.10

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 23 Apr 2026, 02:07 PM

Fortis Healthcare's Nomination & Remuneration Committee has approved the grant of 1,32,05,200 stock options to eligible employees under its 2026 ESOP scheme. Each option is exercisable into one equity share at a price of Rs 923.10, which was the closing market price on April 22, 2026. The options will vest over a maximum period of 3 years and have an exercise window of 4 years post-vesting. This move is aimed at aligning employee interests with shareholder value and retaining key talent within the organization.

Grant of 1,32,05,200 options convertible into an equal number of equity shares of Rs 10 face value.
Exercise price fixed at INR 923.10 per share based on the closing price of April 22, 2026.
Vesting schedule spans a maximum of 3 years from the date of grant.
Exercise period extends up to 4 years from the date of each vesting of such options.

💡 Investors should monitor the potential equity dilution, which is approximately 1.75% of the current share capital, though the impact will be spread over several years. No immediate action is required as this is a routine long-term incentive plan.

Fortis Healthcare to Conduct Non-Deal Roadshow in Mumbai on April 27-28, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Apr 2026, 05:08 PM

Fortis Healthcare Limited has announced a two-day Non-Deal Roadshow (NDR) scheduled for April 27 and 28, 2026, in Mumbai. The event, organized by JM Financial, will involve in-person one-on-one and group meetings between the company management and institutional investors. The discussions are intended to cover general business updates and industry trends. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these meetings.

Non-Deal Roadshow scheduled for April 27 and 28, 2026, in Mumbai.
Meetings will be held from 09:00 AM to 07:00 PM IST on both days.
Event organized by JM Financial featuring one-on-one and group meeting formats.
Focus remains on general business updates and industry-wide developments.
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 As this is a routine investor engagement activity, no immediate action is required. Investors may look for subsequent analyst notes or research reports that might provide insights into management's outlook on the healthcare sector.

Fortis Healthcare to Conduct Non-Deal Roadshow in Mumbai on April 27-28, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Apr 2026, 05:05 PM

Fortis Healthcare Limited has scheduled a two-day Non-Deal Roadshow (NDR) in Mumbai on April 27 and 28, 2026. Organized by JM Financial, the event will involve in-person one-on-one and group meetings between company management and institutional investors. The sessions are intended to provide general business updates and discuss the current healthcare industry landscape. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Two-day Non-Deal Roadshow scheduled for April 27 and April 28, 2026, in Mumbai.
Meetings organized by JM Financial will run from 09:00 AM to 07:00 PM IST.
Interaction format includes both in-person one-on-one and group meetings with analysts.
Discussions will focus on general business performance and industry-wide trends.
Company confirms that no unpublished price sensitive information will be disclosed.

💡 As this is a routine investor engagement event, no immediate action is required. Investors should look for any subsequent investor presentations or analyst notes that may emerge following these meetings.

Fortis Healthcare Reports Credit Rating Upgrade to AA+ and Timely Servicing of ₹1,550 Cr Debt

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 10 Apr 2026, 12:46 PM

Fortis Healthcare has filed its annual disclosure for corporate bonds for the financial year ended March 31, 2026. A key highlight is the credit rating upgrade by CRISIL from AA to AA+ (Stable) for its debt instruments, reflecting improved creditworthiness. The company successfully paid interest totaling approximately ₹130.47 Crore on its ₹1,550 Crore bond issuances. All payments were made on the due date of December 22, 2025, with no history of defaults reported.

Credit rating upgraded from CRISIL AA to CRISIL AA+ (Stable) on September 1, 2025.
Total outstanding non-convertible securities amount to ₹1,550 Crore across three tranches.
Annual interest payments totaling ₹130.47 Crore were paid on the due date of December 22, 2025.
Reported zero defaults or delays in servicing any debt securities for the financial year.

💡 The credit rating upgrade to AA+ is a positive signal of the company's strengthening balance sheet and operational stability. Investors should view this as a reduction in financial risk, supporting a stable long-term outlook.

Fortis Healthcare Reports Outstanding Debt Securities of ₹1,550 Crore as of March 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Apr 2026, 06:31 PM

Fortis Healthcare has submitted its periodic report on debt securities issued via private placement as required by SEBI regulations. The company currently has three tranches of listed debt totaling ₹1,550 crore, all issued in December 2024. These securities carry a first-year coupon rate of 7.7648% and are scheduled to mature on December 19, 2029. The filing is a standard transparency measure and confirms the current status of the company's long-term debt obligations.

Total outstanding debt through private placement stands at ₹1,550 crore across three tranches.
The debt tranches are valued at ₹500 crore, ₹500 crore, and ₹550 crore respectively.
All securities have a fixed maturity date of December 19, 2029.
The coupon rate is set at 7.7648% for the first year, with annual resets and step-up/step-down provisions.

💡 No immediate action is required as this is a routine regulatory disclosure. Investors should continue to monitor the company's interest coverage ratio and debt-to-equity levels.

Fortis Healthcare Submits Routine SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 04:24 PM

Fortis Healthcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all securities dematerialized or rematerialized during the quarter ended March 31, 2026, have been duly reported to the stock exchanges. This is a standard administrative filing required by all listed companies in India to maintain transparency in shareholding records. The filing indicates that the company's registrar is maintaining proper records of electronic and physical share conversions.

Compliance certificate submitted for the quarter ended March 31, 2026.
Issued by Registrar and Transfer Agent (RTA) KFin Technologies Limited.
Confirms reporting of dematerialized/rematerialized securities to NSE and BSE.
Filing is in accordance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial results for material performance updates.

Fortis Healthcare Subsidiary Receives INR 149.12 Crore Income Tax Demand

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 01 Apr 2026, 11:02 AM

Fortis Healthcare's wholly-owned subsidiary, Fortis Hospitals Limited, has received an assessment order from the Income Tax Authority for the Assessment Year 2021-22. The order raises a significant tax demand totaling INR 149.12 Crores. The company has stated it is currently evaluating all legal options, including filing an appeal or a rectification application against the order. This represents a potential financial liability that could impact the company's cash flows if not successfully contested.

Income Tax demand of INR 149.12 Crores raised against Fortis Hospitals Limited
The demand pertains to the Assessment Year 2021-22
Assessment order was issued on March 27, 2026, and received by the company on March 31, 2026
Management is exploring legal remedies including appeals and rectification applications

💡 Investors should monitor the company's progress in contesting this demand through appeals. While the amount is substantial, the final impact will depend on the outcome of the litigation process.

Fortis Healthcare Subsidiary Receives INR 117.04 Crore Income Tax Demand

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 28 Mar 2026, 02:10 PM

Fortis Healthcare's wholly-owned subsidiary, Fortis Hospitals Limited, has received an Income Tax assessment order for AY 2024-25. The order raises a significant tax demand amounting to INR 117.04 Crores. The company has stated it is currently evaluating legal options, including filing an appeal or a rectification application against the order. This development represents a potential financial liability that could impact the company's cash flows if the demand is upheld.

Income Tax demand of INR 117.04 Crores raised against subsidiary Fortis Hospitals Limited
The tax demand pertains to Assessment Year (AY) 2024-25
Order was issued by the Income Tax Authority on March 27, 2026
Company is exploring legal remedies including appeals and rectification applications

💡 Investors should monitor the progress of the company's appeal against this tax demand as it represents a significant contingent liability. While the company is contesting the order, any unfavorable final ruling would result in a cash outflow of INR 117.04 Crores.

Fortis Healthcare Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 03:58 PM

Fortis Healthcare Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial disclosures. The window will remain shut until 48 hours after the declaration of the audited financial results for the quarter and financial year ending March 31, 2026. This is a standard regulatory procedure to prevent insider trading during the period when sensitive financial information is being finalized.

Trading window closure effective from April 1, 2026.
Closure is related to the audited financial results for Q4 and the full financial year ending March 31, 2026.
The window will reopen 48 hours after the results are officially declared to the stock exchanges.
Compliance maintained under SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine administrative filing and does not impact the company's fundamentals. Investors should monitor for the future announcement of the specific date for the Q4 and FY26 earnings release.

Fortis Healthcare Shareholders Approve ESOP Scheme 2026 with Over 96% Majority

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 18 Mar 2026, 10:27 PM

Fortis Healthcare has received shareholder approval for its new 'Employees Stock Option Scheme 2026' through a postal ballot process. The primary resolution to establish the scheme passed with a 96.59% majority, while extensions of the scheme to employees of subsidiaries and associate companies also received requisite approval. This initiative is designed to align employee interests with long-term shareholder value and improve talent retention across the group. The voting results, finalized on March 18, 2026, indicate strong overall support for the management's incentive plan.

ESOP Scheme 2026 approved with 65.11 crore votes in favor, representing a 96.59% majority.
Grant of options to subsidiary employees passed with a 96.70% majority (65.18 crore votes).
Resolution for associate company employees received 87.58% approval, with 12.42% of votes cast in dissent.
A total of approximately 67.41 crore valid votes were scrutinized for the primary resolution.

💡 Investors should monitor the specific terms of the ESOP grants as they are announced to evaluate the potential equity dilution and impact on earnings per share (EPS).

Fortis Shareholders Approve ESOP Scheme 2026 with Over 96% Majority

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 18 Mar 2026, 10:23 PM

Fortis Healthcare shareholders have approved the implementation of the 'Employees Stock Option Scheme 2026' through a postal ballot. The scheme extends to eligible employees of the company, its subsidiaries, and associate companies to align employee interests with long-term shareholder value. The primary resolution for the company's ESOP was passed with a strong 96.59% majority, while the resolution for associate companies saw a slightly lower but still significant 87.58% approval. This move is aimed at talent retention and performance incentivization across the group.

Resolution to approve Fortis Healthcare Limited ESOP Scheme 2026 passed with 96.59% votes in favor.
Grant of options to subsidiary employees approved with 96.70% majority (65.19 crore votes).
Grant of options to associate company employees approved with 87.58% majority.
Total valid votes for the main resolution reached 67.41 crore shares across 1,290 ballots.
The resolutions were deemed passed on March 18, 2026, following the conclusion of the e-voting process.

💡 Investors should view this as a standard corporate move to retain and incentivize key talent. Monitor the specific details of the grant size in future filings to assess the potential long-term equity dilution.

Fortis Healthcare Reports Nil Activity in Special Window for Physical Share Transfer Re-lodgement

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 16 Mar 2026, 07:49 PM

Fortis Healthcare Limited has submitted a status report regarding the special window for re-lodging physical share transfer requests for the months of January and February 2026. According to the report from KFin Technologies, the company's Registrar and Share Transfer Agent, zero requests were received during these periods. This filing is in compliance with SEBI circulars aimed at streamlining the transfer of physical shares. Since no requests were made or processed, there is no impact on the company's share capital structure or operations.

Zero (NIL) requests received for re-lodgement of physical share transfers in January 2026.
Zero (NIL) requests received, processed, or approved during the month of February 2026.
Compliance filing follows SEBI circulars dated July 2, 2025, and January 30, 2026.
Average time taken for processing requests was recorded as NIL due to lack of applications.

💡 No action is required as this is a routine regulatory update with no material impact on the company's financials or shareholding.

Fortis Healthcare Completes Merger of Four Subsidiaries into Fortis Hospitals

🟢 POSITIVE ⭐ 7/10

M&A 📅 02 Mar 2026, 01:59 AM

Fortis Healthcare has announced that the merger of four of its wholly-owned subsidiaries into Fortis Hospitals Limited (FHsL) became effective on March 1, 2026. The entities absorbed include Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors. This consolidation follows the filing of certified NCLT orders from the Delhi and Chandigarh benches with the Registrar of Companies. The move is designed to simplify the corporate structure and enhance operational efficiency across the group.

Merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited is now effective.
The effective date of the Scheme of Arrangement is confirmed as March 1, 2026.
NCLT orders from Delhi and Chandigarh benches were filed via Form INC-28 with the ROC.
The restructuring aims to reduce administrative overheads and streamline the organizational hierarchy.

💡 Investors should view this as a positive administrative cleanup that simplifies the company's complex subsidiary structure. No immediate portfolio changes are necessary as the entities were already 100% owned.

Fortis Healthcare Q3 FY26: EBITDA Jumps 34.8%, Margin Expands to 22.3% Amid Strategic Acquisitions

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 20 Feb 2026, 01:13 PM

Fortis Healthcare reported a strong Q3 FY26 with consolidated revenues growing 17.5% YoY to INR 2,265 crores, driven by a 19.4% growth in the hospital segment. Operating EBITDA surged 34.8% to INR 505 crores, reflecting significant margin expansion to 22.3% from 19.4% YoY. While reported PAT dipped to INR 197 crores due to a one-off INR 55 crore labor code expense, operational performance remained robust with ARPOB rising 4.5% to INR 2.56 crores. The company continues its aggressive expansion, recently acquiring People Tree Hospital in Bengaluru for INR 430 crores and adding 750 beds during the year.

Consolidated EBITDA grew 34.8% YoY to INR 505 crores with margins expanding 290 bps to 22.3%.
Hospital business revenue increased 19.4% to INR 1,938 crores, supported by a 4.5% rise in ARPOB to INR 2.56 crores.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 crores with plans to expand to 300 beds.
Agilus Diagnostics reported a sharp margin improvement to 23.1% from 14.4% in the previous year.
Net debt stands at INR 2,547 crores (1.24x Net Debt/EBITDA) following recent inorganic growth investments.

💡 Investors should focus on the strong operational margin expansion and the successful integration of new acquisitions. The temporary dip in PAT due to labor code provisions is a non-recurring item, making the core business growth trajectory attractive.

View All FORTIS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Hospital business revenue grew 19.3% YoY to INR 1,974 Cr in Q2 FY26, while the Diagnostics business (Agilus) grew 7.3% YoY to INR 400 Cr. For H1 FY26, Hospital revenue increased 19% to INR 3,812 Cr and Diagnostics grew 7.3% to INR 768 Cr.

Geographic Revenue Split

Pan-India presence with 27 hospitals. Key facilities in Noida, Faridabad, and FEHI (Fortis Escorts Heart Institute) registered revenue growth in excess of 20% YoY in Q2 FY26. Top 10 facilities contribute 73% to hospital revenues with a 20% operating EBITDA margin.

Profitability Margins

Consolidated PAT for Q2 FY26 was INR 329 Cr, up 70.3% YoY. Net profit margin stood at approximately 14.1%. Hospital business operating margins improved 250 bps to 22.5% in H1 FY26 compared to 20% in H1 FY25.

EBITDA Margin

Consolidated Operating EBITDA margin reached 23.9% in Q2 FY26 vs 21.9% in Q2 FY25, a 200 bps improvement. Diagnostics business reported a 26.1% operating EBITDA margin in Q2 FY26, up from 21.5% YoY.

Capital Expenditure

The company plans to incur capital expenditure of INR 800-1,000 Cr per annum over the next couple of years to fund brownfield expansions and medical equipment upgrades.

Credit Rating & Borrowing

Maintains a strong financial risk profile with a net debt-to-EBITDA ratio of 0.96x as of September 30, 2025, compared to 0.16x in 2024, following debt raised for the Agilus stake acquisition.

⚙️ Operational Drivers

Raw Materials

Medical consumables and pharmacy supplies represent the primary operational costs, though specific percentage of total cost is not disclosed. Rebranding costs for Agilus and Fortis were significant one-off expenses in FY25.

Capacity Expansion

Current network includes 27 hospitals. Planned addition of 1,200-1,500 beds over the medium term. Recent additions include Shrimann Superspecialty (228 beds) and a 15-year lease for a 200-bed facility in Greater Noida with expansion potential to 250 beds.

Raw Material Costs

Not disclosed as a specific percentage of revenue; however, hospital operating EBITDA margins of 22.9% suggest a well-managed cost structure despite inflationary pressures in medical supplies.

Manufacturing Efficiency

Occupancy for Q2 FY26 stood at 71% versus 72% in Q2 FY25. ARPOB (Average Revenue Per Occupied Bed) improved 5.8% YoY to INR 2.51 Cr per annum.

Logistics & Distribution

Diagnostics business operates over 410 labs and 4,330 customer touchpoints as of September 30, 2025, to ensure wide retail reach.

📈 Strategic Growth

Expected Growth Rate

17%

Growth Strategy

Growth will be driven by adding 1,200-1,500 beds via brownfield expansion, increasing ARPOB through a better surgical mix (currently 58%), and scaling the diagnostics business. The company also consolidated its stake in Agilus Diagnostics to 89.20% and acquired the 'Fortis' brand for INR 200 Cr to secure long-term brand usage.

Products & Services

Healthcare delivery services including complex surgeries (oncology, cardiac, neurosciences), outpatient consultations, and diagnostic pathology/radiology tests.

Brand Portfolio

Fortis, Agilus Diagnostics (formerly SRL Diagnostics).

New Products/Services

Expansion into digital healthcare with digital channels (website/app) now contributing 29.5% to hospital revenues, growing 20.4% YoY.

Market Expansion

Expansion in Punjab via Shrimann Hospital and Greater Noida. Evaluating integration of Gleneagles portfolio in Hyderabad and Chennai to enter new geographies.

Market Share & Ranking

Among India's leading healthcare delivery companies; Agilus is a leading player in the diagnostics segment with 410+ labs.

Strategic Alliances

Consolidated 89.20% stake in Agilus by buying out PE investors (NJBIF, Resurgence, and IFC). 15-year lease agreement with RR Lifesciences for Greater Noida hospital.

🌍 External Factors

Industry Trends

The industry is shifting toward digital patient acquisition (29.5% of Fortis revenue) and consolidation of diagnostic players. Fortis is positioning itself by expanding brownfield capacity to meet rising demand for specialty care (oncology, neurosciences).

Competitive Landscape

Competes with other major hospital chains like Apollo and Max Healthcare, as well as regional diagnostic labs.

Competitive Moat

Moat is built on a pan-India network of 27 hospitals and a massive diagnostic footprint (4,330 touchpoints). Sustainability is supported by the acquisition of the 'Fortis' brand and high clinical talent onboarding in oncology and cardiac sciences.

Macro Economic Sensitivity

Sensitive to healthcare spending trends and insurance penetration. Regulatory caps on cash transactions above INR 2 lakh impact high-value surgical billing.

Consumer Behavior

Increasing preference for digital booking and preventive health checkups; Agilus preventive portfolio now contributes 13% to its revenue.

Geopolitical Risks

Resumption of international patient revenue is a key driver, which is sensitive to global travel stability and medical tourism policies.

⚖️ Regulatory & Governance

Industry Regulations

Subject to National Pharmaceutical Pricing Authority (NPPA) price caps on medical devices and clinical establishment acts across different states.

Taxation Policy Impact

Tax expense for Q2 FY26 was INR 96.6 Cr on a PBT of INR 425.4 Cr, representing an effective tax rate of approximately 22.7%.

Legal Contingencies

Contingent liabilities of approximately INR 2,622 Cr as of March 31, 2024, including income tax matters and medical negligence. Ongoing Supreme Court-directed investigation by the Delhi High Court into the RHT asset purchase and potential forensic audit.

⚠️ Risk Analysis

Key Uncertainties

Outcome of the Hon’ble Supreme Court/High Court litigation regarding RHT assets and the potential for a forensic audit could impact management focus and financial liability.

Geographic Concentration Risk

Significant revenue concentration in North India (Noida, Faridabad, Shalimar Bagh), though the network is pan-India.

Third Party Dependencies

Dependency on medical specialists and clinical talent; the company recently onboarded specialists in oncology and neurosciences to mitigate talent risk.